Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus irinotecan and temozolomide versus irinotecan plus temozolomide in relapsed or refractory Ewing's sarcoma
jRCT2071220043Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2022
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial in Ewing sarcoma of bone and Ewing sarcoma comparing Abemaciclib + Irinotecan + Temozolomide with Irinotecan + Temozolomide (2 arms). Primary endpoint: Progression-free survival. Started Sep 2022; status: active, not recruiting.
02
Drugs
abemaciclibirinotecantemozolomide
03
Conditions
Ewing sarcoma of boneEwing sarcoma
Beyond the preview
Go deeper on jRCT2071220043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220043.